What percentage of THC (tetrahydrocannabinol) users develop a psychotic disorder?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: March 7, 2026View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Percentage of THC Users That Experience Psychosis

The available evidence does not provide a specific percentage of THC users who develop psychotic disorders, but research demonstrates that cannabis users have approximately 2-3 times the risk of psychosis compared to non-users, with heavy users facing nearly 4 times the risk.

What the Evidence Shows

Risk Magnitude Rather Than Absolute Rates

The research literature consistently reports relative risk rather than absolute percentages of users who develop psychosis. A meta-analysis of 66,816 individuals found that the heaviest cannabis users had an odds ratio of 3.90 (95% CI 2.84-5.34) for developing schizophrenia and other psychotic outcomes compared to non-users 1. An earlier systematic review calculated a fixed-effects odds ratio of 2.9 (95% CI 2.4-3.6) for the relationship between cannabis use and psychosis 2.

Dose-Response Relationship

The risk increases substantially with higher levels of use 3. The American College of Physicians 2024 guidelines note that high doses of THC may be associated with psychosis, particularly given that THC concentrations have nearly doubled from 9% in 2008 to 17% in 2017, with some concentrates reaching 70% THC 3.

Vulnerable Populations at Higher Risk

Certain groups face elevated risk:

  • Adolescent users: Early cannabis use is associated with elevated risk for psychotic disorders in adulthood 3
  • Frequent/daily users: Daily use carries substantially higher risk than occasional use 4
  • High-potency cannabis users: Consumption of high-THC products increases psychosis risk 4
  • Genetic vulnerability: Individuals with specific genotypes (particularly those affecting dopamine function like AKT1) have moderated risk 4

Clinical Context

Among patients presenting to emergency departments with measured serum theophylline concentrations, approximately 10% had concentrations associated with clinical intoxication, though this relates to a different substance and is not directly applicable to cannabis 5.

About one-third of patients with first-episode psychosis are cannabis users 6. Among those who continue using cannabis after developing psychosis, approximately half persist in their use, and continued use is associated with higher relapse rates and more severe positive symptoms 6.

Important Clinical Caveats

  • Cannabis use advances psychosis onset by 2-3 years in those who develop the condition 6
  • The relationship appears causal based on experimental studies showing cannabinoids can induce psychotic symptoms 6
  • Discontinuing cannabis use reduces relapse risk to levels comparable with non-users in those already diagnosed with psychosis 6
  • Recent data shows individuals with psychotic disorders who use cannabis experience 9.53 percentage point increase in 30-day cannabis use following recreational legalization 7

The absence of a specific percentage reflects the complex interplay between dose, potency, age of initiation, genetic factors, and individual vulnerability rather than a limitation of the evidence base.

Related Questions

What is the risk of psychosis associated with THC (cannabis) use, especially in young adults, frequent or daily users, high‑potency (>10% THC) products, and individuals with a personal or family history of psychotic disorders?
What is the recommended management for treatment‑resistant psychosis?
What are the indications, dosing recommendations, and monitoring requirements for Abilify (aripiprazole)?
What is the appropriate dosing of aripiprazole (Abilify) for treating intrusive thoughts?
What is the recommended dosing of aripiprazole (Abilify) for a 14‑year‑old?
What is the risk of psychosis associated with THC (cannabis) use, especially in young adults, frequent or daily users, high‑potency (>10% THC) products, and individuals with a personal or family history of psychotic disorders?
What priority should I assign to ordering a right hip X‑ray (pelvis AP and frog‑leg lateral) for a 62‑year‑old woman with chronic weight‑bearing hip pain, morning stiffness, and limited internal rotation?
For a patient with type 2 diabetes who is taking prednisone 15 mg in the morning and 10 mg in the evening, insulin glargine (Lantus) 10 units twice daily, and an insulin‑to‑carbohydrate ratio of 1 unit per 10 g carbohydrate, if the evening prednisone dose is reduced to 5 mg while the morning dose remains 15 mg, what should the insulin glargine dose and the carbohydrate‑to‑insulin ratio be adjusted to?
How should a COPD exacerbation be classified, what are the treatments for each severity level, and what are the indications for non‑invasive ventilation?
What are the indications to start antifungal therapy in a patient with an aspergilloma?
How should increased intestinal flatus be managed?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.